These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2016-002435-15||Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer||not-yet-due|
|Ongoing||2018-002094-22||A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant NALIRINOX||not-yet-due|
|Ongoing||2018-002095-40||Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with rectal c...||not-yet-due|
|Ongoing||2019-002974-29||A phase II single arm trial evaluating the preliminary efficacy of the combination of 177Lu-DOTATATE and nivolumab in Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated ...||not-yet-due|
|Ongoing||2020-001405-23||Randomized phase II clinical trial of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19.Ruxo-Sim-20 clinical trial.||not-yet-due|
|Ongoing||2020-001548-24||A randomized, single-blind study with a parallel control group on the efficacy and safety of bemiparin at therapeutic dose vs. prophylactic dose in patients hospitalized for COVID-19||not-yet-due|